AZ, Ironwood In $150 Million Alliance To Develop Linzess In China
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca and Ironwood plan a $150 million alliance to develop and market linaclotide, a drug for treating irritable bowel syndrome, approved in the U.S. in August for Forest Laboratories as Linzess.